Hangzhou Tigermed Consulting Co., Ltd. (HNGZY)
USD 4.14
(0.0%)
USD 4.14
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -572.49 Million USD | 21.69% |
| 2022 | -731.08 Million USD | 36.38% |
| 2021 | -1.14 Billion USD | 20.94% |
| 2020 | -1.45 Billion USD | -1197.97% |
| 2019 | -111.98 Million USD | -307.51% |
| 2018 | 53.96 Million CNY | 126.48% |
| 2017 | -203.83 Million CNY | -23.28% |
| 2016 | -165.34 Million CNY | -446.34% |
| 2015 | 47.74 Million CNY | 130.61% |
| 2014 | -155.97 Million CNY | 65.73% |
| 2013 | -455.18 Million CNY | 18.83% |
| 2012 | -560.81 Million CNY | -554.2% |
| 2011 | -85.72 Million CNY | -101.94% |
| 2010 | -42.45 Million CNY | -143.62% |
| 2009 | -17.42 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -3.79 Billion CNY | 6.69% |
| 2024 Q3 | 1.44 Billion CNY | 109.15% |
| 2024 Q2 | 900.86 Million CNY | 123.76% |
| 2023 Q4 | -4.02 Billion CNY | -7.96% |
| 2023 Q3 | -3.73 Billion CNY | 22.64% |
| 2023 FY | -572.49 Million USD | 21.69% |
| 2023 Q1 | -665.67 Million USD | 8.56% |
| 2023 Q2 | -4.82 Billion CNY | -624.77% |
| 2022 Q3 | -688.55 Million USD | 87.18% |
| 2022 Q4 | -727.96 Million USD | -5.72% |
| 2022 FY | -731.08 Million USD | 36.38% |
| 2022 Q1 | -6.18 Billion CNY | 15.57% |
| 2022 Q2 | -5.36 Billion CNY | 13.18% |
| 2021 Q4 | -7.32 Billion CNY | 1.75% |
| 2021 FY | -1.14 Billion USD | 20.94% |
| 2021 Q1 | -1.39 Billion CNY | 85.65% |
| 2021 Q2 | -1.38 Billion CNY | 0.86% |
| 2021 Q3 | -7.45 Billion CNY | -438.23% |
| 2020 Q2 | -573.27 Million CNY | 13.48% |
| 2020 Q3 | -10.67 Billion CNY | -1761.47% |
| 2020 Q4 | -9.73 Billion CNY | 8.74% |
| 2020 FY | -1.45 Billion USD | -1197.97% |
| 2020 Q1 | -662.62 Million CNY | 30.63% |
| 2019 Q3 | -1.4 Billion CNY | -4.24% |
| 2019 Q2 | -1.34 Billion CNY | -6564.39% |
| 2019 Q4 | -955.22 Million CNY | 31.97% |
| 2019 Q1 | 20.83 Million CNY | -61.39% |
| 2019 FY | -111.98 Million USD | -307.51% |
| 2018 Q1 | -195.11 Million CNY | 4.27% |
| 2018 Q3 | -135.3 Million CNY | 21.64% |
| 2018 Q2 | -172.66 Million CNY | 11.51% |
| 2018 Q4 | 53.96 Million CNY | 139.88% |
| 2018 FY | 53.96 Million CNY | 126.48% |
| 2017 Q3 | -174.61 Million CNY | 52.02% |
| 2017 Q1 | -292.47 Million CNY | -76.89% |
| 2017 FY | -203.83 Million CNY | -23.28% |
| 2017 Q4 | -203.83 Million CNY | -16.73% |
| 2017 Q2 | -363.96 Million CNY | -24.44% |
| 2016 Q3 | -157.04 Million CNY | -21.78% |
| 2016 FY | -165.34 Million CNY | -446.34% |
| 2016 Q4 | -165.34 Million CNY | -5.29% |
| 2016 Q2 | -128.95 Million CNY | -157.11% |
| 2016 Q1 | -50.15 Million CNY | -205.06% |
| 2015 FY | 47.74 Million CNY | 130.61% |
| 2015 Q3 | 23.07 Million CNY | 117.78% |
| 2015 Q4 | 47.74 Million CNY | 106.88% |
| 2015 Q2 | -129.78 Million CNY | 6.17% |
| 2015 Q1 | -138.32 Million CNY | 11.32% |
| 2014 Q2 | -365.3 Million CNY | 4.16% |
| 2014 FY | -155.97 Million CNY | 65.73% |
| 2014 Q1 | -381.16 Million CNY | 16.26% |
| 2014 Q4 | -155.97 Million CNY | -264.58% |
| 2014 Q3 | 94.76 Million CNY | 125.94% |
| 2013 Q3 | -522.71 Million CNY | -9.5% |
| 2013 Q4 | -455.18 Million CNY | 12.92% |
| 2013 FY | -455.18 Million CNY | 18.83% |
| 2013 Q1 | -537.94 Million CNY | 4.08% |
| 2013 Q2 | -477.38 Million CNY | 11.26% |
| 2012 Q3 | -557.4 Million CNY | -570.65% |
| 2012 FY | -560.81 Million CNY | -554.2% |
| 2012 Q2 | -83.11 Million CNY | 0.0% |
| 2012 Q4 | -560.81 Million CNY | -0.61% |
| 2011 Q4 | -85.72 Million CNY | 0.0% |
| 2011 FY | -85.72 Million CNY | -101.94% |
| 2010 FY | -42.45 Million CNY | -143.62% |
| 2009 FY | -17.42 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 2.2 Million USD | 26051.573% |
| Arrayit Corporation | 1.05 Million USD | 54334.799% |
| Atlantic International Corp. | 236.49 Thousand USD | 242172.464% |
| Biocept, Inc. | -788 Thousand USD | -72551.23% |
| Bioqual, Inc. | -12 Million USD | -4667.941% |
| CardioGenics Holdings Inc | 22.73 Thousand USD | 2517764.339% |
| DermTech, Inc. | 17.65 Million USD | 3343.028% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| HTG Molecular Diagnostics, Inc. | -7.37 Million USD | -7660.59% |
| iMD Companies, Inc. | 1.11 Million USD | 51402.492% |
| IDenta Corp. | 524.85 Thousand USD | 109176.786% |
| Interpace Biosciences, Inc. | 7.69 Million USD | 7540.755% |
| Integrative Health Technologies, Inc. | -26.95 Thousand USD | -2124015.813% |
| InVitro International | -313.14 Thousand USD | -182721.753% |
| Lumos Diagnostics Holdings Limited | 1.56 Million USD | 36659.587% |
| Many Bright Ideas Technologies Inc. | -713.00 USD | -80293265.217% |
| Medical Imaging Corp. | 3.79 Million USD | 15201.596% |
| NovelStem International Corp. | 3.52 Million USD | 16356.875% |
| Optigenex Inc. | 8.93 Million USD | 6508.027% |
| PharmChem, Inc. | -1.49 Million USD | -38208.8% |
| Proteome Sciences plc | 14.57 Million USD | 4028.359% |
| Response Genetics, Inc | -13.08 Million USD | -4274.841% |
| Rennova Health, Inc. | 14.82 Million USD | 3960.394% |
| RushNet, Inc. | 4.8 Million USD | 12024.811% |
| ScreenPro Security Inc. | 135.58 Thousand USD | 422325.766% |
| Stella Diagnostics Inc. | 6.19 Million USD | 9344.086% |
| StageZero Life Sciences Ltd. | 1.78 Million USD | 32183.166% |
| Todos Medical Ltd. | 38.31 Million USD | 1594.21% |